Search Results Search Sort by RelevanceMost Recent Viewpoint Jan 2006 Is Prenatal Genetic Screening Unjustly Discriminatory? Jeff McMahan, PhD Virtual Mentor. 2006;8(1):50-52. doi: 10.1001/virtualmentor.2006.8.1.oped1-0601. Viewpoint Jan 2006 The Uncertain Rationale for Prenatal Disability Screening David Wasserman, JD and Adrienne Asch, PhD Virtual Mentor. 2006;8(1):53-56. doi: 10.1001/virtualmentor.2006.8.1.oped2-0601. Viewpoint Oct 2005 Teens Deserve More than Abstinence-Only Education Debra Hauser Virtual Mentor. 2005;7(10):710-715. doi: 10.1001/virtualmentor.2005.7.10.oped2-0510. Viewpoint Jan 2004 Activism? Yes! The AMA? Maybe Not Howard Brody, MD, PhD Virtual Mentor. 2004;6(1):60-62. doi: 10.1001/virtualmentor.2004.6.1.oped1-0401. Viewpoint Apr 2014 Inappropriate Obstructions to Access: The FDA’s Handling of Plan B Susan F. Wood, PhD The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions. Virtual Mentor. 2014;16(4):295-301. doi: 10.1001/virtualmentor.2014.16.4.oped1-1404.
Viewpoint Jan 2006 Is Prenatal Genetic Screening Unjustly Discriminatory? Jeff McMahan, PhD Virtual Mentor. 2006;8(1):50-52. doi: 10.1001/virtualmentor.2006.8.1.oped1-0601.
Viewpoint Jan 2006 The Uncertain Rationale for Prenatal Disability Screening David Wasserman, JD and Adrienne Asch, PhD Virtual Mentor. 2006;8(1):53-56. doi: 10.1001/virtualmentor.2006.8.1.oped2-0601.
Viewpoint Oct 2005 Teens Deserve More than Abstinence-Only Education Debra Hauser Virtual Mentor. 2005;7(10):710-715. doi: 10.1001/virtualmentor.2005.7.10.oped2-0510.
Viewpoint Jan 2004 Activism? Yes! The AMA? Maybe Not Howard Brody, MD, PhD Virtual Mentor. 2004;6(1):60-62. doi: 10.1001/virtualmentor.2004.6.1.oped1-0401.
Viewpoint Apr 2014 Inappropriate Obstructions to Access: The FDA’s Handling of Plan B Susan F. Wood, PhD The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions. Virtual Mentor. 2014;16(4):295-301. doi: 10.1001/virtualmentor.2014.16.4.oped1-1404.